Literature DB >> 977133

[Pharmacokinetics of azlocillin, a new semisynthetic, wide-spectrum antibiotic (author's transl)].

K Wirth, M Schomerus, J H Hengstmann.   

Abstract

Azlocillin, a new semisynthetic penicillin with a wide spectrum of antimicrobial activity and a member of the ureidopenicillin group, was administered to ten adults in a dosage of 2 g by intravenous bolus injection. The determination of antibiotic activity in serum and urine demonstrated an average concentration of 58.9 mug/ml after one hour, 28.1 mug/ml after two hours and 6.1 mug/ml after four hours. The total urinary excretion was 60% within six hours. The pharmacokinetic parameters were calculated for the one and two compartment models, respectively. Mathematical analysis according to an open two-compartment model resulted in better curve adjustment as judged from the sum of the deviant squares. The resulting parameters for volume of distribution and rate of elimination show only minor differences however. Similar results were seen on comparison with the respective data for ampicillin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 977133     DOI: 10.1007/BF01638344

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  5 in total

1.  Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.

Authors:  L W Dittert; W O Griffen; J C LaPiana; F J Shainfeld; J T Doluisio
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

2.  The change in serum, urine and renal tissue levels after administration of various doses of carbenicillin.

Authors:  E Iván; M Arr; J Földi
Journal:  Int J Clin Pharmacol       Date:  1972-11

3.  Drug elimination and apparent volume of distribution in multicompartment systems.

Authors:  M Gibaldi; D Perrier
Journal:  J Pharm Sci       Date:  1972-06       Impact factor: 3.534

4.  Theoretical drug levels during multiple dosing in a two-compartment open model.

Authors:  M C Meyer
Journal:  Arch Int Pharmacodyn Ther       Date:  1971-10

5.  Clinical pharmacology of carbenicillin compared with other penicillins.

Authors:  H C Standiford; M C Jordan; W M Kirby
Journal:  J Infect Dis       Date:  1970-09       Impact factor: 5.226

  5 in total
  13 in total

1.  Pharmacokinetic comparison of 5 g of azlocillin every 8 h and 4 g every 6 h in healthy volunteers.

Authors:  R D Lander; R P Henderson; D R Pyszczynski
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

2.  [Azlocillin--a new penicillin against Pseudomonas aeruginosa and other gram-negative bacteria].

Authors:  H B König; K G Metzger; R P Mürmann; H A Offe; P Schacht; W Schröck
Journal:  Infection       Date:  1977       Impact factor: 3.553

3.  Elimination of azlocillin in patients with biliary t-tube drainage.

Authors:  U Gundert-Remy; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 4.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

5.  Pharmacokinetics of mezlocillin in healthy volunteers.

Authors:  T Bergan
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

6.  The pharmacokinetics of furazlocillin in healthy humans.

Authors:  P H Hinderling; U Gundert-Remy; D Förster; W Gau
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

7.  [Azlocillin--a new anti-pseudomonas penicillin. A review of the literature and pharmacokinetic studies].

Authors:  Z Modr; K Dvorácek; I Janků; V Krebs
Journal:  Infection       Date:  1982       Impact factor: 3.553

8.  [In vitro activity of mezlocillin, azlocillin and carbenicillin against bacteroidaceae with particular reference to bacteroides fragilis (author's transl)].

Authors:  H Werner; C Krassemann; J Ungerechts; H J Schmitz
Journal:  Infection       Date:  1977       Impact factor: 3.553

9.  [Azlocillin and mezlocillin: two new semisynthetic acylureido-penicillins (author's transl)].

Authors:  H Lode; U Niestrath; P Koeppe; H Langmaack
Journal:  Infection       Date:  1977       Impact factor: 3.553

10.  [Current chemotherapy of infections caused by Pseudomonas aeruginosa (author's transl)].

Authors:  A Bauernfeind; C Petermüller; M Dietzel
Journal:  Infection       Date:  1979       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.